Start your Trading & Investing Journey with us
Join our channel for Daily Free Trades with Live analysis on Youtube, Trade Setup with Important Levels, and Important Stock Market Updates
Avience Biomedicals IPO Review - Issue Date, Price, GMP, Subscription, Allotment, Lot Size, and Details
Avience Biomedicals IPO Review
Avience Boimedicals Limited is a Noida-based molecular diagnostics and medical devices company engaged in manufacturing and distribution of in-vitro diagnostic (IVD) products, rapid test kits, biochemistry reagents, diagnostic equipment, laboratory consumables, and related healthcare products.
The Company is led by Chairman and Managing Director, Mr. Dharam Deo Choudhary.
The Revenues from operations for the Period ended on January 31, 2026, 2025 and 2024 were ₹ 4194.28 Lakh, ₹ 4596.74 Lakh, and ₹ 2437.27 Lakh, The EBITDA for the the Period ended on January 31, 2026, and Fiscals ended on Mar 31, 2025, and 2024 were ₹ 1033.53 Lakh, ₹ 1141 Lakh and ₹ 407.52 Lakh, The Profit after Tax for the Period ended on January 31 2026, and Fiscals ended on Mar 31, 2025 and 2024 were ₹ 573.96 Lakh, ₹ 733.18 Lakh, and ₹ 214.11 Lakh, respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹ 19.06and post-issue EPS of ₹ 13.18 for FY25. The pre-issue P/E ratio is 10.91x, while the post-issue P/E ratio is 15.78x, against the Industry P/E ratio is 0. The company's ROE for FY25 is 49.89% and RoNW is 49.89% The Annualised EPS is ₹ 12.56x, and P/E is ₹ 16.56x, these metrics suggest that the IPO is Fairly priced.
The Grey Market Premium (GMP) of Avience Boimedicals Limited showing listing gains of 20.2%. Given the company's financial performance and the valuation of the IPO, we recommend Investors to Apply to the Avience Boimedicals Limited , IPO for Listing gain or Long-Term Purposes.
